Search clinical trials for: Aducanumab (BIIB037)

Total 184 results

Biogen
Eisai Co., Ltd.

Completed

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

Healthy Volunteers

United States
Biogen

Completed

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

Alzheimer's Disease

United States
Biogen

Active, not recruiting

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Alzheimer's Disease

Korea, Republic of, United States, Spain, Belgium, Italy, Australia, Canada, Switzerland, Portugal, Taiwan, France, Poland, Germany, Netherlands, Sweden, Austria, Denmark, Japan, United Kingdom, Finland
Biogen

Terminated

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)

Alzheimer's Disease

United States, Spain, Italy, Taiwan, Australia, Denmark, Portugal, Korea, Republic of, Canada, Japan, France, United Kingdom, Austria, Germany
Biogen

Active, not recruiting

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (ENVISION)

Alzheimer's Disease

Canada, United States, Spain, Italy, Australia, Belgium, Portugal, Korea, Republic of, United Kingdom, France, Germany, Sweden, Japan, Brazil, Finland, Poland, Mexico
Biogen

Completed

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

Healthy Volunteer

United States
Biogen

Terminated

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities (EVOLVE)

Cognitive Dysfunction | Alzheimer's Disease

United States
Biogen

Terminated

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)

Alzheimer's Disease

United States, Spain, Belgium, Switzerland, Poland, Canada, Italy, Germany, Netherlands, Sweden, France, Japan, Finland
Biogen

Completed

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

Alzheimer's Disease

United States
Biogen

Completed

Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease (PROPEL)

Alzheimer's Disease

Japan
Eli Lilly and Company

Completed

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Mild Cognitive Impairment (MCI) | Alzheimer Disease

United States
Biogen

Completed

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

Multiple Sclerosis | Acute Optic Neuritis

United States
Biogen

Completed

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

Multiple Sclerosis | Central Nervous System (CNS) Demyelinating Disease

United Kingdom
Biogen

Completed

New Formulation and Food Effect Study of BIIB074

Trigeminal Neuralgia (TN) | Other Neuropathic Pain

United States
Biogen

Terminated

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

Spinocerebellar Ataxia Type 3

United States, Netherlands, Israel, Portugal, United Kingdom, Germany
Biogen

Completed

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

Healthy

United States
Biogen

Completed

Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.

Healthy

United Kingdom
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Germany, Canada, Japan, Finland, Switzerland, Netherlands, Sweden
Biogen

Completed

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

Multiple Sclerosis | Healthy

United States
Biogen

Terminated

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Netherlands, Switzerland
Biogen

Completed

Administration of BIIB028 to Subjects With Solid Tumors

Advanced Solid Tumors

United States
Biogen

Approved for marketing

Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

United States
Ali Rezai
InSightec

Recruiting

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

Mild Cognitive Impairment | Alzheimer Disease 1

United States
Biogen

Completed

Single-Dose Study of a New Formulation of BIIB061

Multiple Sclerosis

United States
Biogen

Completed

Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

Healthy Volunteers

Australia, China
Biogen
Ionis Pharmaceuticals, Inc.

Completed

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C))

Amyotrophic Lateral Sclerosis

United States, Canada, Belgium, France, Australia, Japan, Denmark, Korea, Republic of, United Kingdom, Germany, Italy, Poland
Biogen

Withdrawn

BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs (EMBRACE)

Rheumatoid Arthritis

Canada
Biogen

Withdrawn

802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (SURGE-2)

Trigeminal Neuralgia
Biogen

Terminated

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Parkinson's Disease

Japan
Biogen

Completed

Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

Healthy Volunteer | Alzheimer's Disease

United States
Biogen

Completed

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

Healthy | Parkinson's Disease

United States
Biogen

Completed

Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants

Healthy Volunteer

United Kingdom
Biogen

Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.

Healthy Subjects

United States
Biogen

Completed

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Healthy Volunteers

United States
Biogen

Terminated

Single Ascending Doses of BIIB063 in Healthy Volunteers

Healthy

United Kingdom
Biogen

Not yet recruiting

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (Mass Balance)

Healthy Volunteer
Biogen

Active, not recruiting

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy (DEVOTE)

Muscular Atrophy, Spinal

China, United States, Netherlands, Spain, Korea, Republic of, Taiwan, Australia, Canada, Chile, Saudi Arabia, Poland, Israel, Brazil, Russian Federation, Hungary, Japan, United Kingdom, Italy, Germany, Estonia, Greece, Mexico, Colombia and more
Biogen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

Healthy Volunteers

United States
Biogen
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease (REASON)

Parkinson's Disease

United States, Spain, Israel, Canada, Norway, United Kingdom
Biogen

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Ireland, Netherlands, Switzerland
Biogen

Terminated

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 (RELAY-1 Extend)

Neuropathic Pain From Lumbosacral Radiculopathy

Spain, United Kingdom, Slovakia, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Italy, Latvia, Romania, Serbia, Estonia
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

Healthy

United States
Biogen

Completed

A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults

Healthy Volunteers

United States
Biogen

Withdrawn

A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well (DAISY)

Ischemic Stroke
Biogen

Terminated

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease (SPARK)

Parkinson's Disease

United States, Italy, Spain, United Kingdom, Austria, Israel, Germany, France, Canada
Biogen

Completed

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Biogen

Completed

Absorption, Metabolism, and Excretion Study of BIIB074

Neuropathic Pain

United States
Biogen

Recruiting

A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis (FUSION)

Relapsing Forms of Multiple Sclerosis

Spain, United States, Italy, Switzerland, Germany, Bulgaria, Czechia, Poland, Puerto Rico, Romania
Biogen

Recruiting

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-2)

Lupus Erythematosus, Systemic

China, United States, Belgium, Netherlands, Japan, Romania, Serbia, Canada, Germany, Hungary, Italy, Puerto Rico, Israel, Argentina, Colombia, Czechia, United Kingdom

3

Subscribe